Abstract | Macrophage activation syndrome (MAS) refers to acute overwhelming inflammation caused by a 'cytokine storm'. Although increasingly recognized as a life-threatening complication of various rheumatic diseases, clinically, MAS is strikingly similar to primary and secondary forms of haemophagocytic lymphohistiocytosis (HLH). Not surprisingly, many rheumatologists prefer the term secondary HLH rather than MAS to describe this condition, and efforts to change the nomenclature are in progress. The pathophysiology of MAS remains elusive, but observations in animal models, as well as data on the effects of new anticytokine therapies on rates and clinical presentations of MAS in patients with systemic juvenile idiopathic arthritis (sJIA), provide clues to the understanding of this perplexing clinical phenomenon. In this Review, we explore the latest available evidence and discuss potential diagnostic challenges in the era of increasing use of biologic therapies. NATURE REVIEWS | RHEUMATOLOGY VOLUME 12 | MAY 2016 | 259
Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic diseases caused by excess ive activation and expansion of T lymphocytes and of macrophages that exhibit haemophagocytic activity [1] [2] [3] [4] [5] [6] [7] . These events lead to overproduction of cytokines and a hyperinflammatory state associated with cytopenias, liver dysfunction and coagulopathy, resembling disseminated intravascular coagulation. Another prominent feature of MAS is extremely high levels of serum ferritin, pre sumably originating from activated macro phages. MAS remains a major cause of mortality in paediatric rheu matology with reported death rates as high as 20-30% 6, 7 . Although this complication has been associated with most rheumatic diseases, in paediatrics it is by far most com mon in systemic juvenile idiopathic arthritis (sJIA) 2, 6, 7 . The pathophysiology of sJIA seems to be driven by con tinuous activation of innate immune pathways leading to dysregulated production of proinflammatory cytokines. Therefore, many paediatric rheumatologists view sJIA as an autoinflammatory disorder rather than a classic auto immune disease [8] [9] [10] . IL 1β [11] [12] [13] and IL6 have been suggested as essential cytokines in the pathogenesis of this condition, although the source of the excess IL6 and IL1β activity has not yet been defined.
Due to increasing awareness of MAS, this condition is now recognized more frequently than before and the interest in this syndrome is growing. New observations in animal models and increasing clinical experience with MAS treatment with various biologics shed new light on the role of cytokines in its pathophysiology. Here, we describe the current terminology and the newly proposed classification criteria for MAS, as well as the animal mod els commonly used to study this condition. In addition, we explore new concepts of the underlying pathophysiology. Finally, we review the effects of existing biologic therapies on MAS and likely new therapeutic targets, and discuss the potential impact of these drugs on the performance of current diagnostic criteria.
Defining MAS and HLH
The inflammatory infiltrate in MAS consists mainly of activated T lymphocytes and histologically benign, welldifferentiated macrophages (or histiocytes) that engulf normal haematopoietic cells 17, 18 (FIG. 1) . Among T lymphocytes, CD8 T cells predominate markedly over CD4 T cells (FIG. 2) . The abundance of highly acti vated haemophagocytic histiocytes suggests that MAS belongs to the group of histiocytic disorders known as haemophagocytic lymphohistiocytosis (HLH).
In the current classification of histiocytic disorders, HLH is further divided into primary (or familial) HLH and secondary HLH (also known as acquired or reactive HLH) [19] [20] [21] .
Primary HLH
Primary HLH is not a single disease, but rather a group of rare, autosomal recessive, immune disorders linked to various genetic defects, all affecting the perforinmediated cytolytic pathway. Symptoms of pri mary HLH usually become evident during the first year of life, although cases with onset in adulthood are reported with increasing frequency. The clinical course of primary 1 HLH can be rapidly progressive; such cases eventu ally require haematopoietic stem cell transplantation as definitive treatment 20 . In ~30% of patients with primary HLH, cytolytic dys function is due to lossof function mutations in the gene encoding perforin (PRF1), a protein utilized by cytolytic cells (such as cytotoxic CD8 T lymphocytes or natural killer [NK] cells) to induce apoptosis of target cells via granzyme B 22 . When released in the interface between the cytolytic and the target cell (immune synapse), perforin selfpolymerizes, creating pores in the plasma membrane that enable granzymes to enter the target cell and trigger apoptosis. The genes implicated in three other types of primary HLH (MUNC13-4, STX11 and STXBP2) encode proteins involved in the transport of granules containing perforin and granzyme to the immune synapse [23] [24] [25] . The cytolytic cells in patients with these mutations produce sufficient amounts of perforin, but an impaired ability to release perforin into the immune synapse leads to profoundly decreased cyto lytic activity. Although muta tions in PRF1, MUNC13-4, STX11 and STXBP2 explain disease in the majority of patients with primary HLH, ~40% of familial cases are still awaiting molecular defi nition 26 . Depressed cytolytic function due to abnormal movements of intracellular granules also contributes to the development of HLH in Griscelli syndrome type 2, caused by mutations in RAB27A, and ChediakHigashi syndrome, caused by mutations in LYST [27] [28] . Both these syndromes are also considered primary HLH. In normal physiological conditions, cytolytic cells induce apoptosis of cells infected with viruses or cells undergoing malig nant transform ation. Even moderate defects in the cytol ytic pathway might prolong the survival of target cells, ultimately leading to overproduction of proinflammatory cytokines 29 . Cytolytic cells can also be directly involved in the termination of immune responses by inducing apoptosis of overly activated immune cells [30] [31] [32] . These observations led to the hypothesis that, in HLH, failure to induce apoptosis of target cells by cytolytic cells might delay the contraction stage of the immune response, leading to persistent expansion of activated T lympho cytes and macro phages and escalated production of pro inflammatory cytokines, thus creating a 'cytokine storm' . Xlinked lympho proliferative syndromes type 1 and 2, caused by mutations in SH2D1A and XIAP, respectively, are two other hereditary immuno deficiencies associated with HLH. Genetic defects in these syndromes interrupt activationinduced apoptosis of immune cells, leading to prolonged survival of lympho cytes and thus increased production of cytokines 33, 34 . The onset of HLH symp toms in these patients is usually triggered by EpsteinBarr virus (EBV) infection causing rapid expansion of activated lymphocytes.
Secondary HLH
Secondary HLH can occur at any age. In general, patients tend to have less severe clinical presentations than in pri mary HLH, but mortality in this group is still considered high 20 , and the emergence of the first clinical signs and symptoms can usually be linked to an infection (most commonly EBV or cytomegalovirus [CMV]) or malign ancy [19] [20] [21] . Furthermore, the cytolytic pathway abnormali ties that occur in this condition are generally considered to be acquired 35 . Over the past 3 years, however, the devel opment of secondary HLH in some of these patients has been linked to compound heterozygous or heterozygous hypomorphic mutations that confer a partial dominant negative effect on cytolytic function 36 . These findings make it increasingly difficult to distinguish between primary and secondary HLH. 
Key points
• A 'cytokine storm' is the final pathophysiological pathway in macrophage activation syndrome (MAS), and blocking various cytokines could be an attractive therapeutic strategy • Standard doses of anti-IL-1 and anti-IL-6 biologic therapies do not have a major effect on MAS rates even if the underlying disease responds well to the treatment • Several case reports suggest that anakinra might be effective at least in some patients with systemic juvenile idiophatic arthritis (sJIA)-associated MAS, particularly when used in high doses • Findings from several studies support IFN-γ blockade as a novel therapy for haemophagocytic lymphohistiocytosis (HLH); increasing evidence suggests the same approach could be beneficial in MAS presenting as a complication of rheumatic diseases • The exact mechanism of predisposition to MAS in sIJA is yet to be defined, but might be independent of underlying sJIA activity and similar to infection-associated secondary HLH • Whole-exome/genome sequencing approaches exploring hypomorphic mutations that affect the cytolytic pathway to support this theory might reveal promising therapeutic alternatives a c d b Nature Reviews | Rheumatology
Two 2014 reports described patients with periodic fevers and MASlike features linked to a gainoffunction mutation in NLRC4, which was in turn associated with overproduction of IL1β and IL18, as well as increased pyroptosis 37, 38 . Pyroptosis is morphologically and mech anistically distinct from other forms of cell death. This process is mediated by caspase 1 and is characterized by rapid plasmamembrane rupture and release of proinflammatory intracellular contents. In patients with gainoffunction mutations in NLRC4, MAS like clinical presentation seemed to be induced by a macrophageintrinsic defect in the absence of primary cytotoxic abnormalities. Although haemophagocytosis has been observed in these patients 38 , the extent of patho physiologic and clinical overlap between this clinical entity and primary HLH is yet to be characterized.
MAS as a form of HLH
The extent of clinical similarity between MAS and HLH is striking (TABLE 1) ; not surprisingly, many paediatric rheu matologists prefer to classify MAS as one of the categories among the secondary HLH forms, or 'rheumatic HLH' . Efforts to update the terminology used to describe MAS and HLH are underway (see BOX 1) .
The similarities between HLH and MAS are not lim ited to clinical features. Similarly to patients with HLH, patients with MAS in association with a rheumatic dis ease also have profoundly decreased cytolytic function, although this impairment tends to improve with better control of the activity of the underlying rheum atic disease 39 . These observations suggest that background inflammation is at least partially responsible for this functional abnormality in MAS. Indeed, IL6, a major contributor to the pathogenesis of sJIA, has been shown to induce defective expression of perforin and decreased NK cell cytotoxic activity 40 . The development of cytolytic dysfunction in sJIA and MAS might also be influenced by a genetic component: a study using wholeexome sequencing demonstrated the presence of hypomorphic mutations in primary HLHassociated genes in approx imately onethird of patients with sJIA and MAS 41 . Targeted sequencing of primary HLH genes from patients with sJIAassociated MAS led to similar results in another study 42 . These studies showed a markedly increased fre quency of rare proteinaltering variants of genes involved in the intracellular transport of perforincontaining granules to the cell surface, as well as in the perforin gene itself. Interestingly, PRF1 variants were observed mainly in populations in Europe 43 , but not in North America [41] [42] [43] [44] .
Animal models of HLH and MAS Perforindeficient mice develop many of the clinical features of HLH after infection with lymphocytic choriomeningitic virus, and are considered the model organism for primary HLH 45 . Levels of several cytokines were reported to be elevated in this model -a pattern reminiscent of the cytokine storm seen in HLH. Remarkably, all clinical and laboratory features of this con dition as well as associated mortality can be almost com pletely prevented by elimination of CD8 T lympho cytes or neutralization of IFNγ 45 . IFNγ is known to activate mac rophages; therfore, IFNγ might be critical for triggering the expansion of macrophages in perforindeficient mice. Similar findings have been observed in Rasrelated pro tein Rab27A knockout mice 46 , another model of primary HLH. These findings implicate IFNγproducing CD8 T lymphocytes as the main driving force of HLH, and suggest that this pathway is a potential therapeutic target.
HLHlike features can also be induced in healthy mice by repeated administration of CpG, a Tolllike receptor 9 (TLR9) ligand 47 . This model is thought to closely reflect the pathology of secondary HLH that occurs in the con text of infections, as continuous stimulation of TLR9 mimics infection. Although serum ferritin levels are only mildly elevated in these animals, and despite the need for additional blockade of IL10 to induce overt haemo phagocytosis, many clinical features seen in this model are reminiscent of HLH (such as cytopenias and liver dysfunction) 47 . The role of IFNγ in this model has been assessed by several groups. Behrens et al. 47 demonstrated that in these animals, IFNγ was produced mainly by den dritic cells (DCs) and NK cells rather than CD8 T lym phocytes. Interestingly, in a later study by the same group, IFNγknockout mice subjected to repeated administra tion of CpG developed immunopathologies and haemo phagocytosis comparable to wildtype mice 48 . However, IFNγknockout mice did not become anaemic and had greater numbers of splenic erythroid precursors, suggest ing that IFNγ contributes to the development of anaemia but might not be required for other MAS features 48 . In a more recent study using the same model, De Min et al. 49 neutralized IFNγ by repeated admin istration of anti IFNγ antibodies. The investigators confirmed neutral ization of IFNγ activity by measuring circulating levels of IFNγinduced chemokines such as CXCL9. In this study, clinical and laboratory features dependent on IFNγ were not limited to anaemia, but included weight loss, splenomegaly, hyperferritinaemia, cytopenia and liver inflammation 49 . Despite some discrepancies, all studies utilizing the CpG model of MAS described herein clearly Nature Reviews | Rheumatology a b
Figure 2 | T cells in bone marrow inflammatory infiltrate in MAS.
Immunohistochemical assessment of the T lymphocyte infiltrate in a bone marrow biopsy from a patient with macrophage activation syndrome (MAS) presenting as a complication of systemic juvenile idiopathic arthritis (sJIA). a | Immunohistochemical staining with anti-CD8 antibodies shows numerous CD8 + T lymphocytes; b | CD4 staining shows only rare CD4 + T lymphocytes.
link chronic TLR stimulation with the development of an HLHlike phenotype. These findings might be relevant for the pathogenesis of MAS, as gene expression signa tures reflecting continuous activation of TLR-IL1 recep tor (IL1R)induced signalling pathways have also been reported in sJIA 50 . Other observations with potential relevance to MAS have been made in mice genetically modified to over produce IL6 (REF. 51 ). The rationale for the development of this model was based on data implicating IL6 as the main cytokine in the pathogenesis of sJIA [14] [15] [16] Findings in mice that overproduce IL6 might reflect the pathology of MAS that occurs in the setting of autoinflammation or autoimmunity more accurately than other animal mod els of haemophagocytic syndromes. In these mice, mac rophages chronically exposed to IL6 have an exaggerated response to TLR stimulation, which is used as a surro gate for acute infection 51 . Mice overexpressing IL6 have reduced survival when compared with wildtype mice, and develop MASlike features, including cytopenia and increased serum levels of ferritin. These observations sug gest that IL6driven background inflammation, as seen in sJIA, can lead to exaggerated responses of macrophages to inflammatory stimuli induced by infection and thus contribute to MAS develop ment. Background inflamma tory activity also seems to have a role in the emergence of MASlike phenotypes in patients with a gainoffunction mutation in the NLRC4 gene, leading to overproduction of IL1β and IL18 (REFS 37, 38) .
Proposed MAS pathophysiology model
Serum IFNγ levels in patients with MAS are markedly high compared with patients with active sJIA without MAS 52, 53 . The emergence of clinical features of MAS in sJIA patients often corresponds to an increase in levels of IFNγ induced chemokines 53 and neopterin, a catabolic product of guanosine triphosphate released by IFNγ activated macrophages 54 . Furthermore, extremely high serum levels of soluble IL2 receptor subunitα (sIL2Rα), presumably shed by cytotoxic CD8 T lymphocytes, are a consistent finding in patients with MAS that could be a useful diagnostic marker 55 . Histopathological evaluation of inflammatory infiltrates in MAS lesions also reveals abundant CD8 T lymphocytes that produce proinflam matory cytokines, including IFNγ 17 . Combined, these observations suggest that, in keeping with findings from animal models, extensive activation and expansion of cytotoxic CD8 T lymphocytes producing IFNγ and other macrophageactivating cytokines are also likely to be central to the pathogenesis of MAS. Subsequently, prolonged stimulation of monocytes and macrophages with these cytokines results in excessive activation and expansion of these cells. These final pathways leading to the development of overt MAS seem similar to those in primary HLH. The upstream events, however, might be more complex and have several components (FIG. 3) . Similar to primary HLH, depressed cytolytic activity also seems to be an important factor in MAS. The genetic defects contributing to the development of this cytolytic dysfunction are usually lowpenetrance, mainly heterozy gous variants and, therefore, might only trigger MAS in combination with the background inflammatory activ ity of sJIA. In other words, persistent activation of TLR signalling pathways as observed in sJIA and chronic IL6 exposure might further suppress cytolytic function and exaggerate responses of macrophages to inflammatory stimuli. Intercurrent infection, a common trigger of MAS, associ ated with an additional surge in macrophage acti vation by cytokines such as IFNγ, further amplifies the inflammatory response, leading to escalating production of cytokines and ultimately creating a cytokine storm. Indeed, in both MAS and HLH, remarkably high levels of circulating cytokines, including IFNγ, IL2, macrophage colonystimulating factor (MCSF), IL1, IL6, IL18 and TNF, as well as cytokine inhibitors such as soluble TNF receptors and IL1R antagonist (IL1Ra), have been reported [56] [57] [58] . The relative importance of these cytokines, however, is not clear. High levels of a particu lar cytokine that strongly correlate with disease activity do not necessarily constitute causality. By contrast, the effects of biologic therapies that block specific cytokines on the risk of developing MAS and its clinical presenta tion can provide valuable clues for understanding the pathophysiology of this clinical phenomenon.
Effects of biologic therapy on MAS As mentioned earlier, IL1β [11] [12] [13] and IL6 (REFS 14-16) have been implicated as important cytokines in sJIA patho physiology. Encouraging findings from small studies involving treatment of sJIA with drugs targeting these cytokines 12, 15 led to large phase III trials with the IL6receptor inhibitor tocilizumab and the IL1β inhib itor canakinumab 13, 16 . In these trials, 60-70% of patients achieved ACR70 (70% improvement according to ACR criteria). Furthermore, more than onethird of patients achieved clinical remission. Adequate control of the underlying disease was expected to protect against MAS, as sJIA disease activity was thought to contribute to the development of this complication. Surprisingly, com plete protection was not observed in either trial, even in patients whose underlying sJIA was wellcontrolled 13, 16 . In the following sections we review the effect of IL1 and IL6inhibiting biologics on the rates and clinical features of MAS in patients with sJIA.
IL-1-inhibiting agents
Anakinra. Anakinra is a recombinant, nonglycosylated form of human IL1Ra. Anakinra blocks the biologic activity of both IL1α and IL1β by competitively inhib iting their binding to IL1R. Despite a lack of phase III trials, anakinra is now widely used for the treatment of sJIA and, occasionally, MAS. Marked improvement in response to anakinra in sJIAassociated MAS after inade quate response to corticosteroids and ciclosporin has been described in many case reports [59] [60] . By contrast, in two reports of the experience with anakinra in sJIA in sev eral paediatric rheumatology centres, occurrence of MAS was described in children treated with doses of 1-2 mg/kg daily [61] [62] . In some of these patients, however, features of MAS improved after the dose of anakinra was increased. Overall, the exact effect of anakinra on rates of MAS in sJIA patients is unknown. The consensus is that anakinra, particularly at higher doses, might be effective at least in some patients with sJIAassociated MAS. However, MAS occurs even when disease activity of the underlying sJIA is controlled by regular treatment with anakinra.
Canakinumab. Canakinumab is a highaffinity, fully human monoclonal antiIL1β antibody designed to exclusively bind and neutralize human IL1β 13 . It does not bind IL1α or IL1Ra. In the early stages of two phase III trials of canakinumab in sJIA, MAS was reported as an adverse event, prompting the formation of an independ ent adjudication committee. Members of the committee
Box 1 | Development of the terminology for MAS and HLH
From a historical perspective, the terms haemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) were introduced at approximately the same time. The classification of histiocytic disorders was initially proposed by the Histiocyte Society in 1987 (REF. 84 ). The first comprehensive clinical descriptions of the syndrome now known as MAS were first published in the early 1980s 1, 2 . In 1985, Hadchouel et al. 2 linked this clinical phenomenon to extensive proliferation of macrophagic histiocytes with pronounced haemophagocytic activity, and the term MAS was eventually introduced by the same group a few years later 3 . Suggestions to replace the term MAS with secondary HLH first appeared in the literature in 2002 . A survey of paediatric rheumatologists and haematologists presented at the 2015 Annual Meeting ofthe International Histiocyte Society revealed that both groups were in favour of using a single term to describe these patients. Interestingly, many haematologists felt that, as a large proportion (up to 40%) of patients with HLH did not display overt haemophagocytosis, the word haemophagocytic within the term HLH might not be appropriate, whereas the term lymphohistiocytosis should certainly be preserved. Efforts to update the contemporary classification of the histiocytic disorders and align terminology used by haematologists and rheumatologists are currently in progress and, in collaboration with the WHO, the revised classification and nomenclature on histiocytic disorders is due to be included in the upcoming 11 th version of the International Classification of Diseases.
had full access to the entire sJIA clinical database for both trials and reviewed all events suspected to be MAS based on specific adjudication criteria (see Supplementary infor mation S1 (table)). Of 323 patients with sJIA enrolled in the trials, including the openlabel extension phase (total 669 patientyears of exposure) 13 , 17 (5.3%) experienced events classified as probable MAS (complete criteria are provided elsewhere 63 ) whilst treated with canakinumab (2.8 events per 100 patientyears) 63 . Two patients had two separate episodes of MAS. The existing literature suggests that 7-17% of all patients with sJIA develop fullblown MAS 7 ; the proportion of patients developing MAS in the canakinumab trials seems to be just below this range. Furthermore, the incidence of MAS observed in the trials was similar to the incidence of MAS in sJIA patients reported from a paediatric rheumatology centre in Cincinnati, USA (4-6 MAS events per 100 patient years; A.A.G., personal observation). These observations suggest that IL1 inhibition with canakinumab does not have a major effect on the risk of developing MAS. Surprisingly, even when underlying sJIA was controlled with this treatment in the two phase III trials, occurrence of MAS was not prevented. In almost all MAS events in these studies, infection was a trigger and clinical and lab oratory features of MAS did not seem to be substantially modified by the treatment.
In addition to the 19 probable MAS events in 17 patients, 10 events in nine patients treated with canaki numab were classified as possible MAS 63 . These patients developed laboratory features consistent with MAS and fever, but no other typical clinical features of MAS. All these events were identified through a search of the clinical and laboratory database for the two phase III trials using predefined laboratory criteria (ferritin ≥500 μg/l; elevated transaminase(s); or leukopenia and/or thrombocytopenia). Surprisingly, none of these events were reported as MAS by the treating physicians, but had been interpreted as flares of sJIA triggered by intercurrent infection. Management of these events was limited to a moderate increase in the dose of corticosteroids 63 . The timely increase in corticosteroid dose is likely to have prevented the progression to overt lifethreatening MAS in these patients, as laboratory abnormalities were con sistent with MAS, perhaps reflecting the early stages of this syndrome (or 'subclinical MAS'). In fact, five of the 10 events satisfied the new classification criteria for MAS in sJIA listed in BOX 2. One important conclusion from these observations is that even mild worsening of sJIA features in a patient treated with canakinumab, especially if triggered by infection, should prompt additional labora tory investigations to rule out subclinical MAS that might require modification of treatment and close monitoring.
Rilonacept.
Rilonacept is a recombinant protein in which the extracellular domains of the IL1R type I and IL1R accessory protein are fused with each other as well as with the Fc portion of human IgG 1 . The extracellular domains of the IL1R components have strong affinity for both IL1α and IL1β and, therefore, intravenous administra tion of this fusion protein leads to neutralization of both cytokines. Another unique feature of rilonacept is that it can also potentially bind to IL1Ra 64 . In a phase III trial of rilonacept in sJIA, patients were randomly allocated in a 1:1 ratio to receive either 4 weeks of placebo followed by Nature Reviews | Rheumatology 20 weeks of rilonacept or to receive 24 weeks of rilona cept, resulting in a doubleblind placebocontrolled phase (weeks 0-4) and a phase of active treatment for all partici pants (weeks . Patients who benefited from rilona cept treatment were eligible for enrolment in the longterm openlabel extension phase (24 weeks to 21 months) 64 . In this trial, corticosteroids were increased or started in case of emergence of any clinical feature suggestive of MAS. Overall, rilonacept demonstrated efficacy in controlling active sJIA. One episode of definite MAS was reported by the investigator. In this patient, MAS was triggered by EBV infection during the openlabel extension phase when underlying sJIA was controlled.
Does the specific agent matter? Data generated in the trials described above raise the question of whether the various IL1inhibiting agents might differ in terms of their effect on MAS. As discussed earlier, several case reports suggest that anakinra might be effective in at least some patients with sJIAassociated MAS, while canakinumab administered at doses of 4 mg/kg monthly does not have a major effect on the risk of develop ing MAS or on its clinical features. The reason for the observed differences is unclear, as both biologics neu tralize IL1β activity. Anakinra neutralizes both IL1α and IL1β activity whereas canakinumab is specific only for IL1β, so it would seem important to assess the poten tial role of IL1α in the pathogenesis of MAS. However, the fact that MAS has been seen in sJIA patients treated with rilonacept, which also neutralizes IL1α, makes this possibility less likely. The effect of dosing could be another important factor. In most case reports describing successful use of anakinra in MAS, daily doses of up to 10 mg/kg were administered, whereas MAS is known to occur in patients treated with doses of 1-2 mg/kg per day, although exact rates have yet to be assessed. In the clinical trials of canakinumab in sJIA, the monthly dose did not exceed 4 mg/kg. It is possible that this dose may not be sufficient to neutralize excessive IL1β activity in MAS. The effect of higher doses of canakinumab on MAS has not been studied.
IL-6-inhibiting agents: tocilizumab
Tocilizumab is a humanized monoclonal antibody that inhibits IL6mediated signalling by binding to the soluble and membranebound IL6 receptors (sIL6R and mIL6R, respectively). An independent adjudication committee examined all cases reported as MAS by inves tigators, as well as all cases of increased transaminases, in a phase III clinical trial of tocilizumab in sJIA performed in Europe, Australia and the USA (112 patients, 403 patient years of exposure), in a separate sJIA phase III trial (149 patients, 326 patientyears), and in a postmarketing sur veillance program in Japan (366 patients, 524 patient years) 16, 65, 66 . In total, 22 events were adjudicated as definite (n = 11) or potential (n = 11) MAS in 21 (3.3%) of the 627 patients with sJIA included in the entire database (see Supplementary information S1 (table) for criteria). On the basis of exposure to tocilizumab, the calculated rates of definite and potential MAS in the three cohorts were 1.24, 1.84 and 2.10 events per 100 patientyears, respectively.
Combining all definite and potential MAS cases from the three cohorts yielded a rate of 1.8 events per 100 patient years. In two of the five cases reported in the phase III trial performed in the USA, Europe and Australia, the develop ment of MAS might have been secondary to withdrawal of tocilizumab therapy, to administration of a partial dose, or to both.
Treatment with tocilizumab has also been suggested to modify some MAS features. In the events that occurred during tocilizumab treatment in the phase III trial in the USA, Europe and Australia, clinical features of MAS were milder than expected. Moreover, these episodes also seemed to present less commonly with hepatomegaly. In almost threequarters of all cases, Creactive protein (CRP) levels remained within the normal range 16, 66 . Given the role of IL6 in inducing the acutephase response of the liver, this observation is not unexpected. Ferritin levels were also lower than expected in at least some cases. Similar observations have been documented by other groups 67, 68 . In addition, a trend towards decreased levels of serum fibrinogen, lowered platelet counts and moreextensive elevation of hepatic enzymes than in typical episodes of MAS was observed in all three cohorts.
In conclusion, data from the tocilizumab clinical trials and postmarketing surveillance suggest that IL6 inhibi tion does not provide full protection against MAS, despite reports that clinical presentation of this syndrome might be modified in tocilizumabtreated patients. Moreover, the excellent response of sJIA features to tocilizumab with simultaneous development of MAS features in some patients also suggests that the role of IL6 in MAS development might be limited 68 .
Pathophysiological implications
Taken together, the observed rates of MAS in phase III clinical trials of tocilizumab and canakinumab show that, in sJIA, therapeutic strategies aimed at the inhibition of either IL1 or IL6 do not provide full protection against MAS, even if the underlying sJIA is well controlled. One conclusion is that neither IL1 nor IL6 is the only driver contributing to development of MAS. Although direct evidence from animal models and indirect evidence from humans suggest that IL6 might be a contributing factor in the development of MAS, data from clinical trials on IL1 or IL6 inhibitors in sJIA suggest that IL1 or IL6, or both, might be dispensable. These findings also suggest that the risk of developing MAS has additional components, such as genetic factors or other inflammatory cytokines, that are not completely abrogated by controlling the underlying sJIA activity with agents that inhibit IL6 or IL1. Considering the close clin ical resemblance between MAS and secondary HLH, the potential role of hypomorphic genetic variants in genes associated with primary HLH should be considered. In the presence of these variants in HLHassociated genes, an encounter with certain microorganisms could trigger MAS in patients with sJIA even if the underlying disease has responded well to agents inhibiting IL1 or IL6. Consistent with this idea, the development of MAS in patients with wellcontrolled sJIA from the trials described above was almost always triggered by infection [63] [64] [65] [66] . Furthermore, targeted sequencing of HLHassociated genes [41] [42] [43] [44] , and wholeexome sequencing in patients with sJIAassociated MAS 41 , revealed an enrichment for rare proteinaltering variants in genes capable of affecting the cytolytic pathway that is dependent on granules. These findings suggest that the genetic contribution of this clini cal phenomenon needs to be explored further. One should also consider the possibility that cytokines other than IL1 or IL6 have a central role in MAS pathophysiology.
A role for IL-18?
Over the past 5 years, interest in the role of IL18 in the pathogenesis of sJIA in general and in MAS in particu lar has increased. Strikingly high serum levels of IL18 have been observed in patients with sJIA [69] [70] [71] , in sharp contrast to only moderately elevated levels of IL18 seen in other rheumatic diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) 72, 73 . Patients with high levels of IL18 are more likely to have systemic manifestations than arthritis as the predominant feature of sJIA, and also seem to be more likely to develop MAS 69 . The emergence of MAS features in these patients is asso ciated with a further increase in IL18 levels 69 , which pos sibly reflect the extent of macrophage activation given that macrophages seem to be the main source of IL18 in patients with MAS 70 . Consistent with this hypothesis, levels of IL18 correlate with ferritin -another marker of macrophage activation -in adultonset Still disease 71 . Finally, comparable IL18 levels have also been observed in primary and secondary HLH 74 , as well as in patients with a MASlike syndrome linked to NLRC4 mutations 37 . Therefore, the use of IL18 levels as a potential marker for those at risk of developing MAS in adultonset Still disease, and perhaps also in sJIA, has been suggested [69] [70] [71] . IL18 was originally described as an IFNγinducing factor 75 . The IL18 receptor system is similar to the one utilized by IL1 and, not surprisingly, IL18 shares downstream effector pathways with critical immu noregulatory molecules such as TLRs and IL1. The activity of IL18 is counterregulated by a highaffinity, naturally occurring IL18 binding protein (IL18BP). In humans, increased disease severity has been associ ated with an imbalance of IL18 to IL18BP, leading to high levels of unbound IL18 (REFS 71, 74, 75) . It has been assumed that the IL18-IL18BP imbalance might con tribute to Tlymphocyte and macrophage activation in HLH 74 . However, in many patients with sJIA, plasma IL18 levels remain above normal even in clinical remis sion 69 . In the absence of IL12 (a cytokine that is not increased in sJIA), IL18 can divert immune responses from the proinflammatory type 1 helper T (T H 1) cells to the antiinflammatory T H 2 cells; therefore, IL18 might be part of an immunoregulatory negativefeedback loop. On the other hand, Chiossone and colleagues 76 examined the role of IL18 in perforindeficient mice infected with murine CMV. Uncontrolled viral replication in these mice is associated with many features of HLH and MAS includ ing pancytopenia, hepatic dysfunction, haemophagocy tosis and death 76 . Administration of synthetic IL18BP ameliorated liver damage in these mice; however, pro duction of proinflammatory cytokines was still detected, and no change in overall survival was observed. These findings suggest that further work using different animal models is needed to better characterize the role of IL18.
What about blocking IFN-γ?
As discussed earlier, IFNγ has a pivotal role in sev eral models of HLH; when this cytokine is neutralized, survival improved substantially in animal models 45, 46 79 . Three independent gene expression studies have failed to find a prominent IFNγinduced signature in the peripheral blood monocytes of children with active sJIA but no clinical features of MAS 11, 50, 80 . The absence of IFNγ activity is not limited to periph eral blood cells, but could also be observed in inflamed tissues. Thus, expression of IFNγinduced chemokines (CXCL9 and CXCL10) in synovial tissue from patients with sJIA is hardly detectable, in contrast to very high levels of these chemokines in tissue from patients with oligoarticular or polyarticular JIA 79 . The absence of the IFNγ signature in sJIA does not seem to be caused by abnormal responsiveness to IFNγ. In fact, monocytes from patients with sJIA incubated with exogenous IFNγ often have exaggerated responses to this cytokine 79 . In contrast to sJIA, evidence suggests that IFNγ is essential for the pathogenesis of MAS. Episodes of MAS in sJIA commonly occur when elicited by viral infections, which are known to activate IFNγinduced pathways. One histopathological study of inflammatory infiltrates in tissues affected by MAS showed numerous IFNγproducing T cells in close proximity to activated haemophagocytic histiocytes 17 . Furthermore, children with MAS exhibit increased levels of neopterin, a prod uct normally released by macrophages stimulated with interferons 52 . Another 2015 study, focused on longitu dinal cytokine changes in serum of patients with sJIA, showed that IFNγ itself and IFNγinduced chemokines increased markedly with the emergence of clinical fea tures of MAS, and returned to normal ranges after resolution of this complication 53 . Furthermore, IFNγ and IFNγinduced chemokines (CXCL9 in particu lar) strongly correlated with many laboratory features of MAS. Neutralization of IFNγ in the MAS model using IL6 transgenic mice led to a great improvement in survival and a considerable decrease in ferritin lev els 53 . Collectively, these observations raise the ques tion of whether IFNγ could also be an appropriate therapeutic target in MAS.
Implications for diagnosis of MAS Increasing experience of MAS in patients receiving var ious biologic anticytokine therapies provides valuable insights into the pathophysiology of this syndrome, but also underscores new diagnostic challenges in this pop ulation. The diagnosis of MAS is difficult, but owing to increased awareness of this complication, it is recognized more and more frequently. A fall in platelet count and erythrocyte sedimentation rate, in combination with persistently high CRP and increasing levels of serum Ddimers, are early signs of impending MAS in a febrile patient with an active rheumatologic condition. Other features indicative of MAS are hyperferritinaemia, cyto penias involving other cell lines (white blood cells and red blood cells), liver dysfunction, coagulopathy, decreasing serum fibrinogen and increasing triglycerides. Diagnosis is usually confirmed by presence of haemophagocytic macrophages (or histiocytes) in bone marrow, but this feature might not be apparent in the early stages of MAS.
In 2014, a set of classification criteria for MAS com plicating sJIA was developed through a combination of expert consensus and analysis of patient data (see BOX 2) .
In crossvalidation analyses, the criteria revealed a sensi tivity of 0.72-0.76 and a specificity 0.97-0.99 . Prospective validation is still required to further scruti nize the performance of the new criteria. Another point to consider is that these criteria were developed using clinical data generated before the introduction of IL1 and IL6 inhibitors for the treatment of sJIA. How these criteria will perform in patients who develop MAS whilst treated with biologic therapy is unclear, as IL6 inhibition tends to decrease ferritin levels and some patients treated with tocilizumab develop neutropenia, liver enzyme elevation and thrombocytopenia.
Conclusions
A cytokine storm is a consistent feature in patients with primary and secondary HLH, including MAS, as well as in animal models of this clinical phenomenon. Therefore, targeting specific cytokines might be an attractive thera peutic approach in such patients. The fact that biologic agents neutralizing IL6 and IL1 are highly effective treatments for sJIA -a rheumatic disease strongly associ ated with MAS -raised hopes that the same strategies would be successful to prevent MAS. However, phase III clinical trials of canakinumab and tocilizumab in sJIA clearly demonstrated that these treatments do not pro vide protection against MAS, and suggest that IL1 and IL6 might not have a central role in the pathogenesis of this syndrome. Current translational research has been focused on IL18 and IFNγ, with IFNγ emerging as a new attractive therapeutic target. The conduct of these trials also underscored potential limitations of the new classification criteria for MAS in patients treated with biologics. As such, additional validation of these criteria will be necessary.
